
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences is a promising investment opportunity due to its strong pipeline of novel therapies designed to overcome resistance to cancer immunotherapies, including its personalized cancer vaccine IFx-2.0. In addition, its DCF-based valuation methodology gives a total market value of $636M, with a 12-month price objective of $10 per share. However, the company does face risks such as negative clinical results, delays in pipeline advancement, and competition in the checkpoint inhibitor market. Long-term dilution risk should also be considered.
Bears say
TuHURA Biosciences is facing multiple challenges as they enter the final stages of their clinical trials, which may result in a delay of potential FDA approval and commercialization of their key therapies. Additionally, the recent decline in their stock price shows a lack of investor confidence, potentially due to uncertainties surrounding the company's financials and future prospects. While upcoming value inflection points provide opportunities for the stock, the company must navigate these challenges successfully in order to see positive growth. Additionally, the company's reliance on a single reportable segment for all of their activities may pose a significant risk in the event of any setbacks or failures in their clinical trials.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares